Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    Online

    What is this Study about?

    Surveying opinions on how to improve diversity in dementia research.

    Eligibility Criteria

    You are eligible to participate if you are:

    1) Involved in dementia research or services

    AND / OR

    2) from an underserved group* in dementia research.

    3)Aged 19 +

    3)Able to complete the web-based survey in one of the following languages: English, French, Chinese (simplified), Punjabi, Inuktitut.

    *Underserved groups in dementia research include: Racial/ethnic minorities (i.e., South Asian, Chinese, Black, Filipino, Arab, Latin American, Southeast Asian, West Asian, Korean, Japanese, or other racial/ethnic minority) Indigenous populations (i.e., First Nations, Inuit, Métis, or other Indigenous group), Sexual/gender minorities (i.e., the LGBTQ2S+ community), Individuals living in rural and/or remote communities, Individuals living with a disability, Individuals with low social and economic conditions.

    Recruitment End Date

  • Observational Study
    Online & In-Person

    What is this Study about?

    A dementia diagnosis impacts the cognitive, functional, and physical abilities of those diagnosed, which will influence their ability to perform activities of daily living including meal preparation and eating. Persons living with dementia can experience a range of difficulties while eating that will impact their ability to consume adequate food and fluids, which include but are not limited to swallowing, chewing, and self-feeding difficulties. Consequently, persons living with dementia are at increased risk of malnutrition and negative health outcomes. The objective of this study is to understand the experience of persons’ living with dementia or diagnosed memory problems and/or their caregivers in managing eating challenges and swallowing problems in the community.

    Eligibility Criteria

    You are eligible to participate if you:
    - Speak English
    - A person with memory problems experiencing eating challenges or swallowing problems in the community
    - OR if you are or were a caregiver to a person with memory problems with eating challenges or swallowing problems.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

    Eligibility Criteria

    Age 50 - 85
    Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
    Must have a study partner

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.

    Eligibility Criteria

    60+
    Diagnosis of Alzheimer's disease
    Must have a study partner

    Recruitment End Date

  • Observational Study
    Online

    What is this Study about?

    Interested in learning how to better support people with dementia through the process of driving cessation? Take part in an online learning program about driving and dementia while participating in a research study. This program aims to equip HCPs with the knowledge and confidence to support people with dementia and their family/friend carers through the often challenging process of driving cessation. The objective of this study is to assess the impact of the e-learning program on HCPs’ knowledge, confidence and competence about driving cessation in the context of dementia. Information will be collected via questionnaires and interviews.

    Eligibility Criteria

    You are eligible to participate in this research if you are a healthcare provider such as a primary care physician, geriatrician, geriatric psychiatrist, nurse practitioner, occupational therapist or medical trainee/student who cares for people with dementia as part of your practice.

    Recruitment End Date

  • Clinical Trial
    Online

    What is this Study about?

    The goal of the proposed SYNERGIC-2 TRIAL (SYNchronizing Exercises, and Remedies to GaIn Cognition@home) is to evaluate cognitive improvements from personalized multidomain interventions that target multiple dementia risk factors delivered at home to older adults with Mild Cognitive Impairment (MCI).

    Eligibility Criteria

    - Aged 60-85 years.

    - Concerned about memory or thinking problems.

    - Have access to internet at home.

    - Ability to speak English.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.

    Eligibility Criteria

    You are eligible to participate if you meet the following criteria:

    • Age ≥ 55; females must be post-menopausal

    • DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)

    • sMMSE ≤ 24

    • Clinically significant agitation based on IPA definition

    • Stable cognition-enhancing medication for at least 3 months prior to study enrolment

    • Availability of a caregiver to accompany participant to study visits and to participate in the study

    • Ability to speak English

    Recruitment End Date

  • Clinical Trial
    Online & In-Person

    What is this Study about?

    To examine the effects of a stress management program on well-being, stress, and cognition in family caregivers of someone with dementia or a related neurodegenerative disorder. We will be recruiting participants from 2023 - 2027.

    Eligibility Criteria

    - are a primary family caregiver of a person with dementia or a related neurodegenerative disorder.

    - have access to a computer with high-speed internet; and feel comfortable using email and Zoom (a secure online meeting platform).

    - have a video camera on your device. To ensure safety of participants during the program sessions, it is important that participants turn on their video camera. Keeping the video camera on is also important to build trust within the group sessions and when interacting with the researchers.

    - are willing to be randomised to one of 3 groups, even if it is not your preferred group.

    - are able to commit to a synchronous 8-week online group-based program (described below) and complete daily prescribed daily home practices.

    - are able to commit to three assessment sessions: one baseline assessment, one post-program assessment, one 12-month follow-up assessment.

    - agree to audio recording of interview sessions and portions of the assessment that require accurate verbal data collection.

    - are able to provide blood samples, potentially after a 12-hour fast.

    - are able to travel to a LifeLabs clinic for biomarker collection.

    - agree to refrain from participating in new studies or programs during the 8-week study session.

    - meet the screening criteria during the pre-screening interview.

    - ability to speak English.

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.

    Eligibility Criteria

    Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.

    Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.

    Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.

    Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.

    Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.

    Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.

    Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.

    Have not undergone any significant head trauma or surgery in the past 6 months.

    Are not pregnant or planning to become pregnant during the duration of the study.

    Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.

    Ability to speak English and French

    Recruitment End Date